Hochgradig therapierelevante Studien, an denen das Studienzentrum der Neurologischen Praxis beteiligt ist

aktuelle Auswahl

EAN 2024: June 29-July 2, 2024; Helsinki, Finland: OzEAN interim analysis: treatment satisfaction, QoL, and fatigue in RRMS patients after 1-year ozanimod use in Germany

Goadsby PJ1, Reuter U1, Hallström Y1, Broessner G1, Bonner JH1, Zhang F1, Sapra S1, Picard H1, Mikol DD1, Lenz RA1.
A Controlled Trial of Erenumab for Episodic Migraine.
N Engl J Med. 2017 Nov 30;377(22):2123-2132. doi: 10.1056/NEJMoa1705848.

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.
The Lancet Volume 391, No. 10127, p1263–1273, 31 March 2018

Stephen L Hauser , ASCLEPIOS I and ASCLEPIOS II Trial Groups
Ofatumumab versus Teriflunomide in Multiple Sclerosis
N Engl J Med 2020 Aug 6;383(6):546-557.